Oncopeptides
Pre-Approval PRO BETAInactive Company
No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 5/27/2021
Pipeline by Phase
Therapeutic Focus
Clinical Trials (9)
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
Started: 6/12/2017
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
Started: 12/21/2020
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
Started: 8/28/2018
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Started: 8/4/2020
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Started: 12/28/2016
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
Started: 4/12/2018
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Started: 8/6/2020
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
Started: 5/27/2021
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Started: 7/1/2013